Genetic inactivation of ATRX leads to a decrease in the amount of telomeric cohesin and level of telomere transcription in human glioma cells

Molecular and Cellular Biology

Volumn 35, Issue 16, 2015, Pages 2818-2830

  Eid, Rita ^a   Demattei, Marie Véronique ^a   Episkopou, Harikleia ^b   Augé Gouillou, Corinne ^a   Decottignies, Anabelle ^b   Grandin, Nathalie ^a   Charbonneau, Michel ^a  

^a UNIVERSITÉ DE TOURS   (France)

^b DE DUVE INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ATRX PROTEIN; COHESIN; PROTEIN; RNA POLYMERASE II; UNCLASSIFIED DRUG; UNTRANSLATED RNA; ATRX PROTEIN, HUMAN; CELL CYCLE PROTEIN; CHROMATIN; DNA HELICASE; NONHISTONE PROTEIN; NUCLEAR PROTEIN; TELOMERASE;

ARTICLE; CANCER CELL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA TRANSCRIPTION; DOWN REGULATION; EMBRYO; FEMALE; GENE INACTIVATION; GLIOMA CELL; GLIOMA CELL LINE; GLIOMA STEM CELL; HCT116 CELL LINE; HEK293 CELL LINE; HELA CELL LINE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; TELOMERE; TELOMERE HOMEOSTASIS; CHROMATIN; GENETIC TRANSCRIPTION; GENETICS; GLIOMA; METABOLISM; RNA INTERFERENCE; TUMOR CELL LINE; ULTRASTRUCTURE;

CELL CYCLE PROTEINS; CELL LINE, TUMOR; CHROMATIN; CHROMOSOMAL PROTEINS, NON-HISTONE; DNA HELICASES; GLIOMA; HUMANS; NUCLEAR PROTEINS; RNA INTERFERENCE; RNA POLYMERASE II; RNA, UNTRANSLATED; TELOMERASE; TELOMERE; TELOMERE HOMEOSTASIS; TRANSCRIPTION, GENETIC;

EID: 84937932035     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.01317-14     Document Type: Article

References (52)

1. Palm W, de Lange T. 2008. How shelterin protects mammalian telomeres. Annu Rev Genet 42:301-334. http://dx.doi.org/10.1146/annurev .genet.41.110306.130350
2. de Lange T. 2009. How telomeres solve the end-protection problem. Science 326:948-952. http://dx.doi.org/10.1126/science.1170633
3. Artandi SE, DePinho RA. 2010. Telomeres and telomerase in cancer. Carcinogenesis 31:9-18. http://dx.doi.org/10.1093/carcin/bgp268
4. Nandakumar J, Cech TR. 2013. Finding the end: recruitment of telomerase to telomeres. Nat Rev Mol Cell Biol 14:69-82. http://dx.doi.org/10 .1038/nrm3505
5. Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA, Reddel RR. 1997. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 3:1271-1274. http://dx.doi.org/10.1038/nm1197-1271
6. Cesare AJ, Reddel RR. 2010. Alternative lengthening of telomeres: models, mechanisms and implications. Nat Rev Genet 11:319-330. http://dx .doi.org/10.1038/nrg2763
7. Durant ST. 2012. Telomerase-independent paths to immortality in predictable cancer sub-types. J Cancer 3:67-82. http://dx.doi.org/10.7150/jca .3965
8. Heaphy CM, Subhawong AP, Hong SM, Goggins MG, Montgomery EA, Gabrielson E, Netto GJ, Epstein JI, Lotan TL, Westra WH, Shih IM, Iacobuzio-Donahue CA, Maitra A, Li QK, Eberhart CG, Taube JM, Rakheja D, Kurman RJ, Wu TC, Roden RB, Argani P, De Marzo AM, Terracciano L, Torbenson M, Meeker AK. 2011. Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol 179:1608-1615. http://dx.doi.org/10 .1016/j.ajpath.2011.06.018
9. Henson JD, Hannay JA, McCarthy SW, Royds JA, Yeager TR, Robinson RA, Wharton SB, Jellinek DA, Arbuckle SM, Yoo J, Robinson BG, Learoyd DL, Stalley PD, Bonar SF, Yu D, Pollock RE, Reddel RR. 2005. A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res 11:217-225.
10. Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, Bettegowda C, Rodriguez FJ, Eberhart CG, Hebbar S, Offerhaus GJ, McLendon R, Rasheed BA, He Y, Yan H, Bigner DD, Oba-Shinjo SM, Marie SK, Riggins GJ, Kinzler KW, Vogelstein B, Hruban RH, Maitra A, Papadopoulos N, Meeker AK. 2011. Altered telomeres in tumors with ATRX and DAXX mutations. Science 333:425. http://dx.doi.org/10.1126/science.1207313
11. Schwartzentruber J, Korshunov A, Liu XY, Jones DTW, Pfaff E, Jacob K, Sturm D, Fontebasso AM, Quang DK, Tönjes M, Hovestadt V, Albrecht S, Kool M, Nantel A, Konermann C, Lindroth A, Jäger N, Rausch T, Ryzhova M, Korbel JO, Hielscher T, Hauser P, Garami M, Klekner A, Bognar L, Ebinger M, Schuhmann MU, Scheurlen W, Pekrun A, Frühwald MC, Roggendorf W, Kramm C, Dürken M, Atkinson J, Lepage P, Montpetit A, Zakrzewska M, Zakrzewski K, Liberski PP, Dong Z, Siegel P, Kulozik AE, Zapatka M, Guha A, Malkin D, Felsberg J, Reifenberger G, von Deimling A, Ichimura K, Collins VP, Witt H, Milde T, Witt O, Zhang C, Castelo-Branco P, Lichter P, Faury D, Tabori U, Plass C, Majewski J, Pfister SM, Jabado N. 2012. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482:226-231. http://dx.doi.org /10.1038/nature10833
12. Bérubé NG. 2011. ATRX in chromatin assembly and genome architecture during development and disease. Biochem Cell Biol 89:435-444. http://dx .doi.org/10.1139/o11-038
13. Ritchie K, Seah C, Moulin J, Isaac C, Dick F, Bérubé NG. 2008. Loss of ATRX leads to chromosome cohesion and congression defects. J Cell Biol 180:315-324. http://dx.doi.org/10.1083/jcb.200706083
14. Sampl S, Pramhas S, Stern C, Preusser M, Marosi C, Holzmann K. 2012. Expression of telomeres in astrocytoma WHO grade 2 to 4: TERRA level correlates with telomere length, telomerase activity, and advanced clinical grade. Transl Oncol 5:56-65. http://dx.doi.org/10.1593/tlo.11202
15. O'Callaghan N, Dhillon V, Thomas P, Fenech M. 2008. A quantitative real-time PCR method for absolute telomere length. Biotechniques 44:807-809. http://dx.doi.org/10.2144/000112761
16. Deng Z, Wang Z, Stong N, Plasschaert R, Moczan A, Chen HS, Hu S, Wikramasinghe P, Davuluri RV, Bartolomei MS, Riethman H, Lieberman PM. 2012. A role for CTCF and cohesin in subtelomere chromatin organization, TERRA transcription, and telomere end protection. EMBO J 31:4165-4178. http://dx.doi.org/10.1038/emboj.2012.266
17. Episkopou H, Kyrtopoulos SA, Sfikakis PP, Fousteri M, Dimopoulos MA, Mullenders LHF, Souliotis VL. 2009. Association between transcriptional activity, local chromatin structure, and the efficiencies of both subpathways of nucleotide excision repair of melphalan adducts. Cancer Res 69:4424-4433. http://dx.doi.org/10.1158/0008-5472.CAN-08-3489
18. Henson JD, Cao Y, Huschtscha LI, Chang AC, Au AYM, Pickett HA, Reddel RR. 2009. DNA C-circles are specific and quantifiable markers of alternative-lengthening-of-telomeres activity. Nat Biotechnol 27:1181-1186. http://dx.doi.org/10.1038/nbt.1587
19. Yeager T, Neumann A, Englezou A, Huschtscha L, Noble J, Reddel R. 1999. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res 59:4175-4179.
20. Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF, Rodriguez FJ, Rosemberg S, Oba-Shinjo SM, Nagahashi Marie SK, Bettegowda C, Agrawal N, Lipp E, Pirozzi C, Lopez G, He Y, Friedman H, Friedman AH, Riggins GJ, Holdhoff M, Burger P, McLendon R, Bigner DD, Vogelstein B, Meeker AK, Kinzler KW, Papadopoulos N, Diaz LA, Yan H. 2012. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 3:709-722.
21. Kannan K, Inagaki A, Silber J, Gorovets D, Zhang J, Kastenhuber ER, Heguy A, Petrini JH, Chan TA, Huse JT. 2012. Whole exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget 3:1194-1203.
22. Liu XY, Gerges N, Korshunov A, Sabha N, Khuong-Quang DA, Fontebasso AM, Fleming A, Hadjadj D, Schwartzentruber J, Majewski J, Dong Z, Siegel P, Albrecht S, Croul S, Jones DT, Kool M, Tonjes M, Reifenberger G, Faury D, Zadeh G, Pfister S, Jabado N. 2012. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 124:615-625. http://dx.doi.org/10.1007/s00401-012-1031-3
23. Nguyen DN, Heaphy CM, de Wilde RF, Orr BA, Odia Y, Eberhart CG, Meeker AK, Rodriguez FJ. 2013. Molecular and morphologic correlates of the alternative lengthening of telomeres phenotype in high-grade astrocytomas. Brain Pathol 23:237-243. http://dx.doi.org/10.1111/j.1750-3639 .2012.00630.x
24. Bower K, Napier CE, Cole SL, Dagg RA, Lau LMS, Duncan EM, Moy EL, Reddel RR. 2012. Loss of wild-type ATRX expression in somatic cell hybrids segregates with activation of alternative lengthening of telomeres. PLoS One 7:e50062. http://dx.doi.org/10.1371/journal.pone.0050062
25. Lovejoy CA, Li W, Reisenweber S, Thongthip S, Bruno J, de Lange T, De S, Petrini JHJ, Sung PA, Jasin M, Rosenbluh J, Zwang Y, Weir BA, Hatton C, Ivanova E, Macconaill L, Hanna M, Hahn WC, Lue NF, Reddel RR, Jiao Y, Kinzler K, Vogelstein B, Papadopoulos N, Meeker AK, ALT Starr Cancer Consortium. 2012. Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet 8:e1002772. http://dx .doi.org/10.1371/journal.pgen.1002772
26. Silvestre DC, Pineda Marti JR, Hoffschir F, Studler J-M, Mouthon M-A, Pflumio F, Junier M-P, Chneiweisse H, Boussin FD. 2011. Alternative lengthening of telomeres in human glioma stem cells. Stem Cells 29:440-451. http://dx.doi.org/10.1002/stem.600
27. Heaphy CM, Schreck KC, Raabe E, Mao XG, An P, Chu Q, Poh W, Jiao Y, Rodriguez FJ, Odia Y, Meeker AK, Eberhart CG. 2013. A glioblastoma neurosphere line with alternative lengthening of telomeres. Acta Neuropathol 126:607-608. http://dx.doi.org/10.1007/s00401-013-1174-x
28. Borodovsky A, Meeker AK, Kirkness EF, Zhao Q, Eberhart CG, Gallia GL, Riggins GJ. 2015. A model of a patient-derived IDH1 mutant anaplastic astrocytoma with alternative lengthening of telomeres. J Neurooncol 121:479-487. http://dx.doi.org/10.1007/s11060-014-1672-2
29. Garrick D, Samara V, McDowell TL, Smith AJ, Dobbie L, Higgs DR, Gibbons RJ. 2004. A conserved truncated isoform of the ATR-X syndrome protein lacking the SWI/SNF-homology domain. Gene 326:23-34. http://dx.doi.org/10.1016/j.gene.2003.10.026
30. Goldberg AD, Banaszynski LA, Noh KM, Lewis PW, Elsaesser SJ, Stadler S, Dewell S, Law M, Guo X, Li X, Wen D, Chapgier A, DeKelver RC, Miller JC, Lee YL, Boydston EA, Holmes MC, Gregory PD, Greally JM, Rafii S, Yang C, Scambler PJ, Garrick D, Gibbons RJ, Higgs DR, Cristea IM, Urnov FD, Zheng D, Allis CD. 2010. Distinct factors control histone variant H3.3 localization at specific genomic regions. Cell 140:678-691. http://dx.doi.org/10.1016/j.cell.2010.01.003
31. Arnoult N, Van Beneden A, Decottignies A. 2012. Telomere length regulates TERRA levels through increased trimethylation of telomeric H3K9 and HP1_. Nat Struct Mol Biol 19:948-956. http://dx.doi.org/10 .1038/nsmb.2364
32. Levy MA, Kernohan KD, Jiang Y, Bérubé NG. 2015. ATRX promotes gene expression by facilitating transcriptional elongation through guanine- rich coding regions. Hum Mol Genet 24:1824-1835. http://dx.doi .org/10.1093/hmg/ddu596
33. Azzalin CM, Reichenbach P, Khoriauli L, Giulotto E, Lingner J. 2007. Telomeric repeat containing RNA and RNA surveillance factors at mammalian chromosome ends. Science 318:798-801. http://dx.doi.org/10 .1126/science.1147182
34. Deng Z, Norseen J, Wiedmer A, Riethman H, Lieberman PM. 2009. TERRA RNA binding to TRF2 facilitates heterochromatin formation and ORC recruitment at telomeres. Mol Cell 35:403-413. http://dx.doi.org/10 .1016/j.molcel.2009.06.025
35. Episkopou H, Draskovic I, Van Beneden A, Tilman G, Mattiussi M, Gobin M, Arnoult N, Londono-Vallejo A, Decottignies A. 2014. Alternative lengthening of telomeres is characterized by reduced compaction of telomeric chromatin. Nucleic Acids Res 42:4391-4405. http://dx.doi.org /10.1093/nar/gku114
36. Kernohan KD, Jiang Y, Tremblay DC, Bonivissuto AC, Eubanks JH, Mann MRW, Bérubé NG. 2010. ATRX partners with cohesin and MeCP2 and contributes to developmental silencing of imprinted genes in the brain. Dev Cell 18:191-202. http://dx.doi.org/10.1016/j.devcel.2009.12 .017
37. Law MJ, Lower KM, Voon HP, Hughes JR, Garrick D, Viprakasit V, Mitson M, De Gobbi M, Marra M, Morris A, Abbott A, Wilder SP, Taylor S, Santos GM, Cross J, Ayyub H, Jones S, Ragoussis J, Rhodes D, Dunham I, Higgs DR, Gibbons RJ. 2010. ATR-X syndrome protein targets tandem repeats and influences allele-specific expression in a sizedependent manner. Cell 143:367-378. http://dx.doi.org/10.1016/j.cell .2010.09.023
38. Wong LH, McGhie JD, Sim M, Anderson MA, Ahn S, Hannan RD, George AJ, Morgan KA, Mann JR, Choo KHA. 2010. ATRX interacts with H3.3 in maintaining telomere structural integrity in pluripotent embryonic stem cells. Genome Res 20:351-360. http://dx.doi.org/10.1101/gr .101477.109
39. Watson LA, Solomon LA, Li JR, Jiang Y, Edwards M, Shin-ya K, Beier F, Bérubé NG. 2013. Atrx deficiency induces telomere dysfunction, en- docrine defects, and reduced life span. J Clin Invest 123:2049-2063. http://dx.doi.org/10.1172/JCI65634
40. Chang FTM, McGhie JD, Chan FL, Tang MC, Anderson MA, Mann JR, Choo KHA, Wong LH. 2013.PMLbodies provide an important platform for the maintenance of telomeric chromatin integrity in embryonic stem cells. Nucleic Acids Res 41:4447-4458. http://dx.doi.org/10.1093/nar/gkt114.
41. Nergadze SG, Farnung BO, Wischnewski H, Khoriauli L, Vitelli V, Chawla R, Giulotto E, Azzalin CM. 2009. CpG-island promoters drive transcription of human telomeres. RNA 15:2186-2194. http://dx.doi.org /10.1261/rna.1748309
42. Flynn RL, Cox KE, Jeitany M, Wakimoto H, Bryll AR, Ganem NJ, Bersani F, Pineda JR, Suvà ML, Benes CH, Haber DA, Boussin FD, Zou L. 2015. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science 347:273-277. http://dx.doi.org/10 .1126/science.1257216
43. Flynn RL, Centore RC, O'Sullivan RJ, Rai R, Tse A, Songyang Z, Chang S, Karlseder J, Zou L. 2011. TERRA and hnRNPA1 orchestrate an RPAto-POT1 switch on telomeric single-stranded DNA. Nature 471:532-536. http://dx.doi.org/10.1038/nature09772
44. Conomos D, Reddel RR, Pickett HA. 2014. NuRD-ZNF827 recruitment to telomeres creates a molecular scaffold for homologous recombination. Nat Struct Mol Biol 21:760-770. http://dx.doi.org/10.1038/nsmb.2877
45. Bhattacharyya MK, Lustig AJ. 2006. Telomere dynamics in genome stability. Trends Biochem Sci 31:114-122. http://dx.doi.org/10.1016/j.tibs .2005.12.001
46. Conomos D, Pickett HA, Reddel RR. 2013. Alternative lengthening of telomeres: remodeling the telomere architecture. Front Oncol 3:27. http://dx.doi.org/10.3389/fonc.2013.00027
47. Picketts DJ, Higgs DR, Bachoo S, Blake DJ, Quarrell OW, Gibbons RJ. 1996. ATRX encodes a novel member of the SNF2 family of proteins:mutations point to a common mechanism underlying the ATR-X syndrome. Hum Mol Genet 5:1899-1907. http://dx.doi.org/10.1093/hmg/5.12.1899
48. Le S, Moore JK, Haber JE, Greider CW. 1999. RAD50 and RAD51 define two pathways that collaborate to maintain telomeres in the absence of telomerase. Genetics 152:143-152.
49. Teng SC, Zakian VA. 1999. Telomere-telomere recombination is an efficient bypass pathway for telomere maintenance in Saccharomyces cerevisiae. Mol Cell Biol 19:8083-8093.
50. Hakin-Smith V, Jellinek DA, Levy D, Carroll T, Teo M, Timperley WR, McKay MJ, Reddel RR, Royds JA. 2003. Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet 361:836-838. http://dx.doi.org/10.1016/S0140-6736(03)12681-5
51. Ulaner GA, Huang HY, Otero J, Zhao Z, Ben-Porat L, Satagopan JM, Gorlick R, Meyers P, Healey JH, Huvos AG, Hoffman AR, Ladanyi M. 2003. Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Res 63:1759-1763.
52. O'Sullivan RJ, Arnoult N, Lackner DH, Oganesian L, Haggblom C, Corpet A, Almouzni G, Karlseder J. 2014. Rapid induction of alternative lengthening of telomeres by depletion of the histone chaperone ASF1. Nat Struct Mol Biol 21:167-174. http://dx.doi.org/10.1038/nsmb.2754